Human factor VII is a single chain, vitamin K-dependent, plasma glycoprotein which is synthesized in the liver (1-3). Prior to secretion into the blood, post translational modification by a vitamin K-dependent carboxylase produces ten-carboxyglutamic acid (gla) residues located in the NH2-terminal portion of the molecule, which facilitate cell membrane binding. Factor VII is proteolytically activated to the serine protease, factor VIIa, during coagulation. Factor VII can be activated by thrombin, factor IXa, factor Xa or factor XIIa. The activation results in cleavage of the single chain molecule on the COOH-terminal side of arginine-152, to produce an NH2-terminal derived light chain (Mr=20,000) and a COOH-terminal derived heavy chain (Mr=30,000) which remain covalently associated by a single disulfide bond. The light chain region contains the gla domain, as well as two growth factor domains which are homologous to human epidermal growth factor (EGF). A single β-hydroxyaspartic acid identified in factor VII is also located in the light chain region. The heavy chain region of factor VIIa contains the catalytic domain. Factor VIIa and the cofactor, tissue factor, may combine on negatively charged cell surfaces in a calcium dependent manner to form the extrinsic factor Xase enzyme complex. This enzyme complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa. The cDNA for factor VII has been isolated and the nucleotide sequence determined (4). Factor VII shares extensive sequence homology with other serine proteases including factor IX, factor X and protein C.

Human factor VII is purified using a combination of conventional techniques (2) and immunoaffinity chromatography (5). The purified protein is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20oC. Purity is determined by SDS-PAGE analysis and activity is measured in a factor VII clotting assay.

Haemtech Biopharma可以运行多种分析技术，以提供对蛋白质药物产品或物质的生化分析，或帮助进行污染物鉴定。我们的测定，测试和技术菜单包括：应用领域IVIG药物的血栓形成性过程中杂质分析与止血有关的抗药物抗体测试（免疫原性）例如抗凝血因子抗体宿主细胞蛋白质的鉴定，定量和缓解在制品和在制品中药品的稳定性和释放测试与止血相关的重组蛋白的效力和纯度测定血浆蛋白分析蛋白质的结构表征翻译后修饰二硫键映射构象变化凝血测定试剂（例如凝血活酶）的表征定制的凝血产品检测应用药代动力学研究分析鉴定/验证工艺/产品验证蛋白质纯化方法的发展强迫降解研究方法高效液相色谱反相（RPC）大小排除（SEC）离子交换（IEC）疏水相互作用（HIC）金属亲和力（IMAC）蛋白质A（用于IVIG分析）SDS页面减少和不减少一维和二维考马斯亮蓝染色银染荧光染色免疫印迹多重分析定量化凝血测定因子分析（II，V，VII，VIII，IX，X，XI，XII，XIII等）PTPTPT行动计划福尔摩斯测试其他ELISA法各种显色测定因子分析（II，V，VII，VIII，IX，X，XI，XII，XIII等）其他翻译后修饰分析糖基化，硫酸化，磷酸化，羟基化，脱酰胺，乙酰化，氧化，氨基甲酸酯化和γ-羧化凝血酶生成测定对于IVIG和其他抗药物抗体ELISA（ADA）抗原料药抗体抗宿主细胞蛋白的抗体抗污染物或分解产物的抗体鉴定未知质谱N端测序残留水分测定顶空真空测量pH值渗透压折光率总蛋白质配方评估